Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
ACADEMIA
3 Existing Drugs Show Inhibitory Effects for SARS-CoV-2 in iPSC Screening
Three existing drugs, including the osteoporosis med raloxifene, demonstrated efficacy in inhibiting RNA viruses such as the new coronavirus, SARS-CoV-2, in a study using iPS cells, Japanese researchers say. In the study, a research group including researchers from Kyoto University’s Center for…
To read the full story
ACADEMIA
- Bromocriptine Found to Slow Alzheimer’s Progression: Kyoto University
July 1, 2022
- NCC Doctor Hails MHLW’s Policy on Use of Clinical Research Data in Regulatory Filing
June 22, 2022
- Kitasato University Spinoff PRD to Develop Lipid Metabolism Control Agents
June 10, 2022
- NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
May 31, 2022
- A Dozen Regional Formularies to Be Launched by Year-End, Pharmacists Must Take the Lead: Society Chief
May 25, 2022
“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…